April 22 (Reuters) - U.S. Food and Drug Administration staff
on Friday formulated voting questions on Sarepta Therapeutics
Inc's muscle wasting drug, ahead of a highly
anticipated meeting of independent panel of experts on Monday to
review the drug.
Read more
No comments:
Post a Comment